{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/itch-widespread/how-this-topic-was-developed/stakeholder-engagement/","result":{"pageContext":{"chapter":{"id":"76e9e0da-5a28-5e8f-a6a8-e08786d8da0e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement","depth":2,"htmlHeader":"<!-- begin field 96597e6f-a39e-48c5-ab4d-a7f2017593db --><h2>Stakeholder engagement</h2><!-- end field 96597e6f-a39e-48c5-ab4d-a7f2017593db -->","summary":null,"htmlStringContent":"<!-- begin item 767ea88c-010b-4fd4-b8aa-a7f20174d91e --><!-- begin field e634d1d7-3cdc-44b5-88a1-a7f2017593db --><h2>Our policy</h2><!-- end field e634d1d7-3cdc-44b5-88a1-a7f2017593db --><!-- begin field fca706b7-0e5b-493f-ae00-a7f2017593db --><p>The external review process is an essential part of CKS topic development. Consultation with a wide range of stakeholders provides quality assurance of the topic in terms of:</p><ul><li>Clinical accuracy.</li><li>Consistency with other providers of clinical knowledge for primary care.</li><li>Accuracy of implementation of national guidance (in particular NICE guidelines).</li><li>Usability.</li></ul><!-- end field fca706b7-0e5b-493f-ae00-a7f2017593db --><!-- begin field bbc30486-cc24-4cb4-a562-a7f2017593db --><h2>Principles of the consultation process</h2><!-- end field bbc30486-cc24-4cb4-a562-a7f2017593db --><!-- begin field cdb405bf-fdad-4eb3-aebc-a7f2017593db --><ul><li>The process is inclusive and any individual may participate.</li><li>To participate, an individual must declare whether they have any competing interests or not. If they do not declare whether or not they have competing interests, their comments will not be considered.</li><li>Comments received after the deadline will be considered, but they may not be acted upon before the clinical topic is issued onto the website.</li><li>Comments are accepted in any format that is convenient to the reviewer, although an electronic format is encouraged.</li><li>External reviewers are not paid for commenting on the draft topics.</li><li>Discussion with an individual or an organization about the CKS&nbsp;response to their comments is only undertaken in exceptional circumstances (at the discretion of the Clinical Editor or Editorial Steering Group).</li><li>All reviewers are thanked and offered a letter acknowledging their contribution for the purposes of appraisal/revalidation.</li><li>All reviewers are invited to be acknowledged on the website.All reviewers are given the opportunity to feedback about the external review process, enabling improvements to be made where appropriate.</li></ul><!-- end field cdb405bf-fdad-4eb3-aebc-a7f2017593db --><!-- begin field 3d0871d7-886d-4cf8-8601-a7f2017593db --><h2>Stakeholders</h2><!-- end field 3d0871d7-886d-4cf8-8601-a7f2017593db --><!-- begin field 1fc22490-62b1-41e0-817a-a7f2017593db --><ul><li>Key stakeholders identified by the CKS team are invited to comment on draft CKS topics. Individuals and organizations can also register an interest to feedback on a specific topic, or topics in a particular clinical area, through the <a href=\"http://cks.clarity.co.uk/get-involved/\" data-hyperlink-id=\"b0a8d70f-46df-49fd-94dd-a99101602201\">Getting involved</a> section of the <a href=\"https://clarity.co.uk/\" data-hyperlink-id=\"eed9dadf-3db4-4bf4-a0a0-a99101602363\">Clarity Informatics</a> website.</li><li>Stakeholders identified from the following groups are invited to review draft topics:<ul><li>Experts in the topic area.</li><li>Professional organizations and societies(for example, Royal Colleges).</li><li>Patient organizations, Clarity has established close links with groups such as Age UK and the Alzheimer&rsquo;s Society specifically for their input into new topic development, review of current topic content and advice on relevant areas of expert knowledge.</li><li>Guideline development groups where the topic is an implementation of a guideline.</li><li>The British National Formulary team.</li><li>The editorial team that develop MeReC Publications.</li></ul></li><li>Reviewers are provided with clear instructions about what to review, what comments are particularly helpful, how to submit comments, and declaring interests.</li></ul><!-- end field 1fc22490-62b1-41e0-817a-a7f2017593db --><!-- begin field 77bea183-b2e0-42fd-aaac-a7f2017593db --><h2>Patient engagement</h2><!-- end field 77bea183-b2e0-42fd-aaac-a7f2017593db --><!-- begin field a26d8100-8165-4427-8ab5-a7f2017593db --><p>Clarity Informatics has enlisted the support and involvement of patients and lay persons at all stages in the process of creating the content which include:</p><ul><li>Topic selection</li><li>Scoping of topic</li><li>Selection of clinical scenarios</li><li>First draft internal review</li><li>Second draft internal review</li><li>External review</li><li>Final draft and pre-publication</li></ul><p>Our lay and patient involvement includes membership on the editorial steering group, contacting expert patient groups, organizations and individuals.</p><!-- end field a26d8100-8165-4427-8ab5-a7f2017593db --><!-- end item 767ea88c-010b-4fd4-b8aa-a7f20174d91e -->","topic":{"id":"98db983b-94d0-57fc-8f85-3c35dffdbc84","topicId":"3ff60e1b-3717-41cc-be12-1871b4284ba6","topicName":"Itch - widespread","slug":"itch-widespread","lastRevised":"Last revised in December 2016","chapters":[{"id":"c31a1ea7-3548-5767-9a55-10f56f4ea14a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"316853c8-d1ca-5613-8c4d-c33ea7c0fd8b","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"64abf965-05aa-566d-999c-e216708a87b3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d34f3906-2823-5407-8f4d-32157480544d","slug":"changes","fullItemName":"Changes"},{"id":"8981751b-abe1-515d-b935-74b8a9b645f8","slug":"update","fullItemName":"Update"}]},{"id":"e1e55a0f-0001-592a-92fd-aacfa519336f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f8e85ce4-cb59-5950-9bb6-f4cc07f650a5","slug":"goals","fullItemName":"Goals"},{"id":"49927afa-5b0d-5fc5-9977-b9fbb4cb4db9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0cdcfdc7-2628-54da-8125-7d0470463e91","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9249d5b2-8df4-5432-adc8-2c07129d2033","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"60200ae0-6fe3-5aac-ba12-bfadcd7364eb","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f57416b9-dc21-5b4f-b045-1a09f5148e92","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b96f535e-5376-53fa-b81c-21c88d0b344f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5e603eed-2553-5ec5-8250-3b6ff59aa984","slug":"definition","fullItemName":"Definition"},{"id":"5d85e75d-599f-583b-843d-861aeef9a901","slug":"causes","fullItemName":"Causes"},{"id":"ac8f2843-31dd-59dc-a6ea-cb91a03a2ff5","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0a022a03-81bf-5f1b-a367-0ecb842aa8b3","slug":"complications","fullItemName":"Complications"}]},{"id":"5520e3e5-dfa1-5437-aeef-2256ca61fbb4","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1cf86197-a1ad-58fc-b46d-d2814ed58a17","slug":"history-examination","fullItemName":"History and examination"},{"id":"3b7bfad0-4337-523a-99e2-a2d249319c14","slug":"investigations","fullItemName":"Investigations"}]},{"id":"5da46787-c48f-5e2c-85d7-6a9a17e04771","fullItemName":"Management","slug":"management","subChapters":[{"id":"136349ec-02aa-57d6-97eb-349a8b186b91","slug":"management-of-widespread-itch","fullItemName":"Scenario: Management of widespread itch"}]},{"id":"a5778d5a-8940-58a1-82e1-4801b7a7ea9f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"df24164a-a18e-5781-af2c-9d5424983d04","slug":"chlorphenamine","fullItemName":"Chlorphenamine"},{"id":"d3b77011-f1f7-5074-ac46-2c0f5e15406a","slug":"hydroxyzine","fullItemName":"Hydroxyzine"}]},{"id":"3bc21e68-6ddb-5e67-9f24-6b13787b7d3c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2ebcf77c-c92c-5ef1-9321-590d2e905484","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bff96b70-ee2f-5eed-a1ab-c601465837a3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"76e9e0da-5a28-5e8f-a6a8-e08786d8da0e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"838c111d-a9e4-5085-b44a-6f220b2e7f9a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"8df3d2d7-e38f-5310-8b24-a8509771d9cd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"74b7f8a8-8f89-5100-ad47-3f6c473ccaf7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f3e3af3a-d360-5e56-8053-6ff53dac1096","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2ebcf77c-c92c-5ef1-9321-590d2e905484","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}